{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:17Z","timestamp":1786119437776,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/bor.0b013e3283369014","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T01:06:54Z","timestamp":1264640814000},"page":"188-193","source":"Crossref","is-referenced-by-count":35,"title":["Progress in the pharmacotherapy of gout"],"prefix":"10.1097","volume":"22","author":[{"given":"John S","family":"Sundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RHU.0b013e3181b562f8","article-title":"Factors associated with recurrent hospital admissions for gout: a case-control study","volume":"15","author":"Hutton","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3899\/jrheum.081296","article-title":"Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients","volume":"36","author":"Barber","year":"2009","journal-title":"J Rheumatol"},{"key":"R3-14-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R6-14-20210128","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R7-14-20210128","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-14-20210128","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/j.1572-0241.2008.02107.x","article-title":"The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study","volume":"103","author":"Pilotto","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R11-14-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R12-14-20210128","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","article-title":"Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan","volume":"22","author":"Chiou","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-14-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002018-200932050-00006","article-title":"Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre","volume":"32","author":"Jonville-Bera","year":"2009","journal-title":"Drug Saf"},{"key":"R14-14-20210128","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-14-20210128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R16-14-20210128","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R17-14-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"R19-14-20210128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R22-14-20210128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R24-14-20210128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R25-14-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R26-14-20210128","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R28-14-20210128","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"J Rheumatol"},{"key":"R30-14-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/dta.24","article-title":"Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase","volume":"1","author":"Kamath","year":"2009","journal-title":"Drug Test Anal"},{"key":"R31-14-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R32-14-20210128","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R33-14-20210128","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/art.23620","article-title":"A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome","volume":"58","author":"Goldbach-Mansky","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R34-14-20210128","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R35-14-20210128","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R36-14-20210128","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"R38-14-20210128","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/jm900210d","article-title":"Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor","volume":"52","author":"Man","year":"2009","journal-title":"J Med Chem"},{"key":"R39-14-20210128","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","article-title":"An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast","volume":"24","author":"Gottlieb","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e3283369014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:08Z","timestamp":1786040288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-201003000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283369014","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}